TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28984095
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia and continuous wound infusion of saline solution
Study: 25091593
Drug: Computer-assisted cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive-behavioral therapy (CBT) - eight sessions led by trained psychologists on a weekly basis
Study: 19441667
Drug: Escitalopram (n=51)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (n=51) with a dose range of 10-20 mg/day
Study: 12771003
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of N-BNP (or BNP) with LVEF
Study: 1506124
Drug: Gincosan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gincosan (60 mg ginkgo biloba + 100 mg ginseng)
Study: 1506124
Drug: Gincosan (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gincosan (120 mg ginkgo biloba + 200 mg ginseng)
Study: 26985728
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - printed literature about alcohol and drug use risks
Study: 20435968
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (local traditional vocational services)
Study: 30179727
Drug: High-cocoa group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cocoa group (4 g/d; 220 mg flavanols)
Study: 30179727
Drug: Middle-cocoa group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-cocoa group (2 g/d; 110 mg flavanols)
Study: 16178946
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg
Study: 17933588
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg
Study: 12174922
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate 11.25 mg subcutaneous injection every three months for 2 years
Study: 12174922
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks)
Study: 10441862
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (0.5 mg/kg per day, adjusted to 0.25 mg/kg per day on alternate days)
Study: 8882570
Drug: Deflazacort (DFC)
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deflazacort (DFC) 0.9 mg/kg/day
Study: 8882570
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) 0.75 mg/kg/day
Study: 30657179
Drug: Yoga program,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program, twice a week for 6 weeks
Study: 27984472
Drug: Weekly spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly spinal stabilization exercises
Study: 12657858
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg parecoxib sodium
Study: 12657858
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib sodium
Study: 12069102
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Q10 (dose-dependent increase)
Study: 26964166
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of shuang huanglian injection (1 mL at each point, three times a week for 2 weeks) and fire needling (once a day for 3 times)
Study: 26964166
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of vitamin C (100 mg, three times a day) and vitamin B2 (20 mg, three times a day) and subcutaneous injection of transfer factor (2 mL, twice a week for 2 weeks)
Study: 21282560
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg
Study: 21282560
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 80 mg
Study: 20236700
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg
Study: 1758394
Drug: Intravenous Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Cyclophosphamide
Study: 6210867
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg/day
Study: 30169215
Drug: PPOIT (Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPOIT (Probiotic and Peanut Oral Immunotherapy)
Study: 22970658
Drug: Flupirtine MR
Normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine MR 400 mg OD
Study: 22970658
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 200 mg OD
Study: 9873237
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for infertile couples
Study: 31173150
Drug: 5-fraction hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fraction hypofractionated stereotactic radiotherapy (HSRT) with a median total dose of 30 Gy (range, 25-35 Gy)
Study: 25940675
Drug: PF‐05231023 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐05231023 (200 mg)
Study: 25940675
Drug: PF‐05231023 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐05231023 (high-dose groups)
Study: 23836190
Drug: Lapatinib 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 900 mg/m² dose bid for 7-14 days (pre-resection treatment)
Study: 23836190
Drug: Lapatinib continuously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib continuously at 900 mg/m² dose bid in phase II study
Study: 19692495
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 microg Se/d as l-selenomethionine)
Study: 7867683
Drug: benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril (10 mg) + amlodipine (5 mg)
Study: 7867683
Drug: amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (5 mg) + benazepril (10 mg)
Study: 17324745
Drug: amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (5 mg)
Study: 2092
Drug: Metoprolol 20
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 20 mg t.i.d.
Study: 11598040
Drug: GBS type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine with alum (12.5 microg dose)
Study: 11598040
Drug: GBS type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine without alum (12.5 microg dose)
Study: 11598040
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of GBS III‐TT conjugate vaccine (12.5 microg dose) for participants with undetectable III CPS‐specific IgG before the first dose
Study: 24552609
Drug: Touch-screen mode
Normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Touch-screen mode of administration
Study: 24552609
Drug: Paper-and-pencil mode
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil mode of administration
Study: 7649579
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments together
Study: 180619
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial ligation and portal venous infusion of 5-fluorouracil
Study: 25368978
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein (HP) infant formula (2.05 g per 100 mL)
Study: 25368978
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein (LP) infant formula (1.25 g per 100 mL)
Study: 16928838
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (Sanofi Pasteur - Adacel and GlaxoSmithKline - Boostrix)
Study: 31418143
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous Molsidomine plus intraventricular sodium nitroprusside (SNP) boluses after TCD-confirmed macrospasm.
Study: 19695841
Drug: Acute Citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Citalopram administration
Study: 19695841
Drug: Chronic Citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic Citalopram administration
Study: 16049380
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel
Study: 12166504
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous corticosteroids
Study: 10514351
Drug: MCP alone
Normalized name: mcpa triisopropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP alone delivered via transdermal iontophoresis (IP) at a constant current of 100 microA/cm(2) for 4 hours.
Study: 1901418
Drug: Fluvoxamine (100‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100‐300 mg/d)
Study: 1901418
Drug: Maprotiline (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (50‐150 mg/d)
Study: 16637075
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of clover phytoestrogens daily for 2 weeks
Study: 10921536
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate supplementation (7.7 pmol, 2200 microg daily for 90 days)
Study: 1676367
Drug: Fenoldopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (100 mg)
Study: 29895309
Drug: Standard high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high protein formula (SHPF) (5 g/100 kcal)
Study: 29895309
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high intact-protein formula (VHPF) (8 g/100 kcal)
Study: 14648210
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen (doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg/body)
Study: 14648210
Drug: THP-COP regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: THP-COP regimen (pirarubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg/body)
Study: 9329344
Drug: Dexamethasone (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (total dose, 10 mg/4 days)
Study: 3948478
Drug: T3 administration
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 administration (30‐80 micrograms/day)
Study: 25623343
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBT-I)
Study: 22998978
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with BBR and EZE
Study: 15922565
Drug: Biological motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological motion task
Study: 2951178
Drug: porcine soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: porcine soluble and isophane, premixed porcine soluble/isophane, porcine soluble and lente, bovine ultralente with three porcine soluble injections before meals (all taken twice daily, and once daily for bovine ultralente)
Study: 2951178
Drug: various insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: various insulin regimens
Study: 30760277
Drug: alteplase-dose arm
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alteplase-dose arm of the ENCHANTED trial (HSRCs)
Study: 25595117
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg tid
Study: 15906123
Drug: Alvimopan 12
Normalized name: alvimopan 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 12 mg
Study: 11050374
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic saline infusion (control)
Study: 11050374
Drug: 5.8% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.8% saline infusion with feedback from the right masseter sEMG
Study: 11050374
Drug: 5.8% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.8% saline infusion with both sEMG and imEMG recorded
Study: 6351890
Drug: Chlorpheniramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (4 mg)
Study: 19417877
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (25 mg)
Study: 766800
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, methotrexate, 5-fluorouracil and vinblastine given intermittently
Study: 28470676
Drug: NDI‐010976 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDI‐010976 (20 mg)
Study: 28470676
Drug: NDI‐010976 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDI‐010976 (50 mg)
Study: 28470676
Drug: NDI‐010976 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDI‐010976 (200 mg)
Study: 26385134
Drug: Room-temperature gel
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room-temperature gel pack (20 °C)
Study: 25004184
Drug: Citalopram as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram as adjunctive therapy to risperidone and olanzapine
Study: 25004184
Drug: Reboxetine as
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine as adjunctive therapy to risperidone and olanzapine
Study: 22798534
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone 2.5 mg/kg
Study: 19650710
Drug: Intravitreal 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 0.2 mL autologous plasmin enzyme (APE) injection
Study: 19650710
Drug: Control eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eye (no injection)
Study: 14754695
Drug: Weekly courses
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly courses of betamethasone
Study: 1565182
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy
Study: 31136656
Drug: High-fat load
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat load with fructose (3 doses of 50 g)
Study: 31136656
Drug: High-fat load
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat load with glucose (3 doses of 50 g)
Study: 25976238
Drug: Oral Morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Morphine Sulfate
Study: 25976238
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of Phenobarbital followed by tapering dose
Study: 22103649
Drug: Tooth-implant-supported fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-implant-supported fixed prostheses (TISPs)
Study: 22103649
Drug: Implant-supported prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported prostheses (ISPs)
Study: 19563522
Drug: Disease-specific nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-specific nutrition treatment (standard diet plus a 400-mL oral supplement or specific enteral formula enriched with protein, 20% of total calories, arginine, zinc, and vitamin C)
Study: 16389668
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg (HYD) with alcohol (ALC)
Study: 16389668
Drug: Rupatadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 20 mg (RUP) with alcohol (ALC)
Study: 16389668
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg (RUP) with alcohol (ALC)
Study: 16296259
Drug: Professional toothcleaning
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional toothcleaning (PTC), oral hygiene instruction, and motivation (test group)
Study: 27372219
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch treatment (21mg) with counseling for 8 weeks
Study: 19819203
Drug: Neutral solution
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral solution
Study: 17713794
Drug: Individual exercise
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual exercise therapy
Study: 1787974
Drug: Clindamycin oral
Normalized name: clindamycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin oral rinse
Study: 6382127
Drug: Flubendazole (FZ)
Normalized name: flubendazole
DrugBank: Flubendazole (DB08974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flubendazole (FZ) treatment
Study: 21440831
Drug: Topical phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phenylephrine (0.1 ml, 10%) administered twice in 5 minutes before surgery
Study: 11122830
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m(2) every 3 weeks
Study: 11122830
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m(2)
Study: 6873418
Drug: Treatment (Ps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (Ps and PA groups)
Study: 22356584
Drug: Sertindole (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (16 mg)
Study: 17685733
Drug: Shared decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared decision making (SDM) program on antipsychotic drug choice
Study: 12109619
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of peripheral insulin sensitivity using HOMA index and a novel index from OGTT
Study: 16775680
Drug: NSAIDs (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (paracetamol or parecoxib/valdecoxib) with piritramid
Study: 12841663
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation with 5-fluorouracil (350 mg/m2/day) and folinic acid (10 mg/m2) administered as intravenous bolus on days 1-5 and 29-33 of radiotherapy, followed by surgery after 4-6 weeks.
Study: 10369641
Drug: Classical pedicle
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical pedicle preparation technique (Group B)
Study: 3492487
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg
Study: 2939794
Drug: Ciprofloxacin 150
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 150 mg
Study: 2939794
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg
Study: 29599611
Drug: Daclatasvir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir plus asunaprevir (DUAL) - daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Study: 29599611
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 weeks) followed by DUAL treatment
Study: 29599611
Drug: DUAL treatment
Normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DUAL treatment during double-blind phase
Study: 26913649
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K deficiency (PIVKA-II > 2 μg/L)
Study: 18771374
Drug: Etoricoxib, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib, 120 mg/day for 7 days
Study: 8388949
Drug: Dexamethasone (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (early treatment group, n = 10)
Study: 3481361
Drug: Incision and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision and drainage with subsequent hospitalization for intravenous antibiotics and hydration
Study: 29782187
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 3,800 IU daily
Study: 31880806
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants (CIs)
Study: 18782876
Drug: High-morning hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-morning hydrocortisone (HC) dose (50% of daily dose in the morning)
Study: 18782876
Drug: High-evening hydrocortisone
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-evening hydrocortisone (HC) dose (50% of daily dose in the evening)
Study: 11107790
Drug: Phagocytic activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phagocytic activity connected with intracellular oxygen metabolism
Study: 6370703
Drug: Theophylline (T)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (T) 5.0 mg/kg